Aqilion is a Swedish biotech company that develops innovative new therapies for diseases caused by chronic inflammation and dysfunctional immune reactions.
The company is mainly active in the idea stage to early clinical development. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the drug to the patients.
Aqilion runs its development programs in a partly virtual organization in close collaboration with selected partners with specific expertise in drug development.
AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden.